BioElectronics Corporation Announces Expansion of Italian Market; TSS Medical Initiates ActiPatch Pharmacy Sales and Marketing

Published: Dec 03, 2007

FREDERICK, Md., Dec. 3 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced an agreement to expand with TSS Medical, Tecnica Scientifica Service, its medical provider distributor into Italy's retail pharmacies. TSS Medical has acquired 10,000 units to initiate the retail product launch.

"TSS Medical had an exceptional response to the ActiPatch products, both at the ESRA Congress in Salerno and at the Congress of Chronic Pain in Genoa. Our sales representatives have reported an extremely positive response to ActiPatch. We are very excited about the market potential for this innovative, drug-free therapy. We are eager to introduce ActiPatch to the retail consumers in Italy. We expect to exceed the minimum annual purchase requirements of the contract and look forward to many successful years of business with BioElectronics," said Mr. Alessio Petricca, Head of Marketing and Operations of TSS Medical.

"We are confident that TSS Medical will play a major role in expanding the use of ActiPatch in Italy. We are pleased to have them launching our exceptional line of retail drug free anti-inflammatory products in the European Common Market", said Kelly Lorenz of BioElectronics.

About TSS Medical:

TSS Medical was established in 1998 and employs 40 sales agents. TSS is headquartered in Torino, Italy and maintains ISO 9000 TUV certification. The company distributes medications and medical devices for postoperative recovery and chronic pain for such leading companies as On Q, Vertis PNT, Anodyne Therapy and others.

For more information visit

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,
+1-301-874-4890, Fax, +1-301-874-6935,

Web site:

Back to news